{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T07:36:14Z","timestamp":1779348974928,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T00:00:00Z","timestamp":1374624000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s12185-013-1395-8","type":"journal-article","created":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T07:35:56Z","timestamp":1374651356000},"page":"483-486","source":"Crossref","is-referenced-by-count":5,"title":["Use of tyrosine kinase inhibitors in a patient with Brugada syndrome and chronic myeloid leukemia"],"prefix":"10.1007","volume":"98","author":[{"given":"Nicola","family":"Sgherza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella Vita","family":"Russo Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Colonna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Carluccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Delia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgina","family":"Specchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,24]]},"reference":[{"key":"1395_CR1","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0735-1097(01)01419-X","volume":"38","author":"Y Miyasaka","year":"2001","unstructured":"Miyasaka Y, Tsuji H, Yamada K, Tokunaga S, Saito D, Imuro Y, et al. Prevalence and mortality of the Brugada-type electrocardiogram in one city in Japan. J Am Coll Cardiol. 2001;38:771\u20134.","journal-title":"J Am Coll Cardiol"},{"key":"1395_CR2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/01.CIR.0000152479.54298.51","volume":"111","author":"C Antzelevitch","year":"2005","unstructured":"Antzelevitch C, Brugada P, Porggrefe M, Brugada J, Brugada R, Corrado D, et al. Brugada syndrome: report of the second consensus conference: endorsed by the heart rhythm society and the European heart rhythm association. Circulation. 2005;111:659\u201370.","journal-title":"Circulation"},{"key":"1395_CR3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","volume":"353","author":"DS Krause","year":"2005","unstructured":"Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172\u201387.","journal-title":"N Engl J Med"},{"key":"1395_CR4","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/02841860903229124","volume":"48","author":"GS Orphanos","year":"2009","unstructured":"Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 2009;48:964\u201370.","journal-title":"Acta Oncol"},{"key":"1395_CR5","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","volume":"12","author":"R Kerkela","year":"2006","unstructured":"Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12:908\u201316.","journal-title":"Nat Med"},{"key":"1395_CR6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ajh.21157","volume":"83","author":"M Tiribelli","year":"2008","unstructured":"Tiribelli M, Colatutto A, Marin L, Barbina G, Qualizza U, Damiani D, et al. Brain natriuretic peptide level as marker of cardiac function in imatinib-treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. Am J Hematol. 2008;83:517\u20138.","journal-title":"Am J Hematol"},{"key":"1395_CR7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.canlet.2005.11.014","volume":"243","author":"YH Park","year":"2006","unstructured":"Park YH, Park HJ, Kim BS, Ha E, Jung KH, Yoon SH, et al. BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett. 2006;243:16\u201322.","journal-title":"Cancer Lett"},{"key":"1395_CR8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nm0107-13a","volume":"13","author":"A Hatfield","year":"2007","unstructured":"Hatfield A, Owen S, Pilot PR. In reply to \u201cCardiotoxicity of the cancer therapeutic agent imatinib mesylate\u201d. Nat Med. 2007;13:13.","journal-title":"Nat Med"},{"key":"1395_CR9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nm0107-13b","volume":"13","author":"C Gambacorti-Passerini","year":"2007","unstructured":"Gambacorti-Passerini C, Tornaghi L, Franceschino A, Piazza R, Corneo G, Pogliani E. In reply to cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2007;13:13\u20134.","journal-title":"Nat Med"},{"key":"1395_CR10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nm0107-15a","volume":"13","author":"G Rosti","year":"2007","unstructured":"Rosti G, Martinelli G, Baccarani M. In reply to \u2018cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019. Nat Med. 2007;13:15.","journal-title":"Nat Med"},{"key":"1395_CR11","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2007-01-070144","volume":"110","author":"E Atallah","year":"2007","unstructured":"Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110:1233\u20137.","journal-title":"Blood"},{"key":"1395_CR12","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ejca.2007.01.018","volume":"43","author":"J Verweij","year":"2007","unstructured":"Verweij J, Casali PG, Kotasek D, Le Cesne A, Reichard P, Judson IR, et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Can. 2007;43:974\u20138.","journal-title":"Eur J Can"},{"key":"1395_CR13","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/cncr.24155","volume":"115","author":"HJ Khoury","year":"2009","unstructured":"Khoury HJ, Guilhot F, Hughes TP, Kim DW, Cortes JE. Dasatinib treatment for Philadelphia chromosome-positive leukemias. Cancer. 2009;115:1381\u201394.","journal-title":"Cancer"},{"key":"1395_CR14","volume-title":"SPRYCEL\u00ae prescribing information (US)","author":"Squibb Bristol-Myers","year":"2007","unstructured":"Bristol-Myers Squibb. SPRYCEL\u00ae prescribing information (US). Princeton, NJ: Bristol-Myers Squibb; 2007."},{"key":"1395_CR15","unstructured":"Bristol-Myers Squibb. SPRYCEL\u00ae summary of product characteristics (EU). Uxbridge, United Kingdom; 2007."},{"key":"1395_CR16","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah N, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531\u201341.","journal-title":"N Engl J Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-013-1395-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-013-1395-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-013-1395-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T01:11:13Z","timestamp":1559437873000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-013-1395-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,24]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["1395"],"URL":"https:\/\/doi.org\/10.1007\/s12185-013-1395-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,24]]}}}